Tis a rather important little subset of OA that is erorsive. 4 Million Group, but it means a backdoor to OA itself since 052 is better than Ankira and no side effects. PG also, it s orphan, and another NDA route. Stock if this is the strategy should be sitting at 15 bucks right not, and 30 on results, yes they are phase 11, but we are a shoe in on NDA based on three sub phase III already running--called EYEGUARD for bechet' type stuff.
Long-timer's will painfully recall the GEVO (called 052 back then) Rheumatoid Arthritis RA trial that completed Phase II testing back in 2009. Xoma never released the results of that trial, and it was just dropped from their pipe without any explanation.They were also pumping 052 RA being better and safer than Anakinra!
Now like F'n magic the same drug now called GEVO is targeting the same IL-1b pathways for yet another form of arthritis, EOA. So, is the inflammation that causes OA, EOA, RA that much different that it selectively works for one form of joint pain, but not another?
It certainly begs the question...... Why does GEVO work for EOA, but it didn't work for Rheumatoid Arthritis?